A venture capital firm based in North America focuses on making primarily Seed-stage investments but maintains flexibility to invest from Pre-Seed through Series A. It typically writes first checks ranging from USD 100,000 to USD 1 million, with a sweet spot around USD 500,000, and is open to follow-on participation. The firm has a flexible capital structure and can invest via equity, SAFEs, convertible notes, or other early-stage instruments. It is comfortable acting as lead, co-lead, or syndicate participant, and generally makes 6-10 new investments per year. While its geographic focus is North America, the firm is open to global opportunities where companies are looking to expand into the U.S. market.
The firm invests primarily in digital health companies and selectively in diagnostics and medical devices, particularly those with significant data value or differentiated data-driven technologies. Within digital health, the firm looks broadly at software and AI-enabled solutions. It is also interested in biotech platform technologies, particularly those enabling delivery or translational efficiency, but tends to avoid single-asset drug candidates. In medtech, the firm is open to all device classifications but shows stronger interest in technologies with clear regulatory or technical differentiation, rather than lightly regulated tools.
A key focus for the firm is the founding team. Team quality is one of the most important decision-making factors, and the firm evaluates teams holistically, including personality, market fit, experience, and leadership traits. The firm prefers to back experienced and well-rounded teams with a clear execution edge.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment